ICER Report Questions Tirzepatide’s Effectiveness Compared to Ozempic and Jardiance; Signos and Dexcom to Launch CGM+AI-Enhanced App Trial; Teladoc Launches Chronic Care Complete Program; Movano Completes Second Glucose Pilot Study; Better Therapeutic Enrolls First Patient in BT-001 RWE Study
A series of cardiometabolic-related news items have been observed: The Institute for Clinical and Economic Review (ICER) released its report on Lilly’s tirzepatide (view article); Signos announced intentions to conduct a health outcomes study (in partnership with Dexcom) investigating CGM+AI-enhanced app use in people without diabetes; Teladoc announced it has launched its Chronic Care Complete program; Movano announced the completion of its second IRB-approved glucose pilot study evaluating its wrist-worn wearable biosensor prototype; and Better Therapeutics announced the first patient has been enrolled in an RWE study evaluating BT-001 for the treatment of T2DM. Below, FENIX provides highlights and insights for the respective new items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.